Clinical recurrence mainly refers to the recurrence of prostate cancer that can be detected clinically by direct examination or by imaging methods. Patients with biochemical recurrence should undergo a comprehensive evaluation including rectal examinations, ultrasound examinations, ultrasound-guided puncture, bone scan and CT, etc. If clinical evidence of prostate cancer recurrence is found, it can be called clinical recurrence of prostate cancer. If clinical recurrence is judged to have occurred, the type of clinical recurrence should be determined, whether it is a local recurrence, regional lymph node metastasis or distant metastasis. The appropriate treatment plan should be selected based on the results of the comprehensive evaluation. Important factors that help to distinguish local recurrence from distant metastasis include the timing of postoperative PSA elevation, PSA velocity, PSA doubling time, pathological stage and Gleason score. The probability of local recurrence only is greater than 80% after radical prostate cancer surgery when: PSA elevation occurs only 3 years after surgery with PSA velocity > 0.75 ng/(ml.y); PSADT ≥ 11 months; Gleason score ≤ 6; pathological stage ≤ pT3a.